E-7449
Cat.No:IE1270 Solarbio
CAS:1140964-99-3
Molecular Formula:C18H15N5O
Molecular Weight:317.34
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Cell Cycle >
E-7449CAS:1140964-99-3
Molecular Formula:C18H15N5O
Molecular Weight:317.34
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:Light yellow to yellow Solid
Qty:
Size:
CAS | 1140964-99-3 |
Name | E-7449 |
Molecular Formula | C18H15N5O |
Molecular Weight | 317.34 |
Solubility | Soluble in DMSO |
Purity | ≥98% |
Appearance | Light yellow to yellow Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
SMILES | O=C1NNC2=C3C1=CC=CC3=NC(CN4CC5=C(C=CC=C5)C4)=N2 |
Target Point | PARP |
Passage | Cell Cycle;DNA Damage/DNA Repair; Epigenetics |
Background | E7449 is a dual PARP1/2 small molecule inhibitor. |
Biological Activity | Stenoparib (E7449) is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC50s of 2.0, 1.0, ~50 and ~50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using 32P-NAD+ as substrate.[1] |
Data Literature Source | [1]. McGonigle S, et al. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget. 2015 Dec 1;6(38):41307-23. |
Unit | Bottle |
Specification | 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.